Antibodies for Combating Parkinson's and Alzheimer's
Article can be found here.
According to a new study, it appears that antibodies developed by researchers at Rensselaer Polytechnic Institute are quite effective in preventing protein particle formations linked to Alzheimer's disease and Parkinson's disease, as well as Type 2 diabetes.
As we have learned previously, both Alzheimer's and Parkinson's share the common trait of inappropriate clumping of proteins, mainly beta-amyloid and lewy bodies, respectively. If these protein masses can be prevented, it is possible the condition is also preventable. In order to combat the formation of aggregations, researchers are utilizing a potent, manufactured antibody. The antibody works by binding to 10 target proteins so they cannot gather together. Typical antibodies only bond to up to 2 proteins, so this new development is much more effective.
The reasoning behind the increased potency is because a very low percentage would be able to cross the blood-brain barrier and be able to get into the brain, where the diseases take hold. By this reasoning it makes sense to try and increase effectiveness so that what little antibody that accesses the brain can preclude as much protein aggregation as possible.
I found this research incredibly interesting because if this development could be put into action and be successfully utilized, who knows what other diseases can be prevented or precluded. Not only that, but through these trials, we can gain a better knowledge of how to improve immunity. Overall, it appears that antibody inhibitors have a promising future in research.
According to a new study, it appears that antibodies developed by researchers at Rensselaer Polytechnic Institute are quite effective in preventing protein particle formations linked to Alzheimer's disease and Parkinson's disease, as well as Type 2 diabetes.
As we have learned previously, both Alzheimer's and Parkinson's share the common trait of inappropriate clumping of proteins, mainly beta-amyloid and lewy bodies, respectively. If these protein masses can be prevented, it is possible the condition is also preventable. In order to combat the formation of aggregations, researchers are utilizing a potent, manufactured antibody. The antibody works by binding to 10 target proteins so they cannot gather together. Typical antibodies only bond to up to 2 proteins, so this new development is much more effective.
The reasoning behind the increased potency is because a very low percentage would be able to cross the blood-brain barrier and be able to get into the brain, where the diseases take hold. By this reasoning it makes sense to try and increase effectiveness so that what little antibody that accesses the brain can preclude as much protein aggregation as possible.
I found this research incredibly interesting because if this development could be put into action and be successfully utilized, who knows what other diseases can be prevented or precluded. Not only that, but through these trials, we can gain a better knowledge of how to improve immunity. Overall, it appears that antibody inhibitors have a promising future in research.
posted by Mallory Carson at 9:23 PM
0 Comments:
Post a Comment
<< Home